Aprecia and Battelle Partner with DARPA and HHS for Agile Pharmaceutical Manufacturing

Aprecia and Battelle Partnered with the US Department of HHS and DARPA

Announcement

Aprecia and Battelle were granted a chance to collaborate with the US Defense Advanced Research Projects Agency (DARPA) as an award agreement to fuel the research program named ‘Establishing Qualification Processes for agile pharmaceutical manufacturing’ (EQUIP-A-Pharma) via a funding raised form the US department of health and human services (HHS) administration for strategic preparedness and response (ASPR), office of industrial base management and supply chain (IBMSC).

The ASPR’s mission is to guide preparation, be responsive, and assist recovery from public health emergencies and disasters. The EQUIP-A-pharma research program will microscope on how a custom small-scale chemical synthesis platform formed by Battelle, merged with Aprecia’s evolving 3D printing technology, can leverage US drug production. This will serve the best quality, and sustainable medications mainly aiming at two medications that are marked s important medicines for the US population.

Impact of EQUIP-A Pharma Program

The EQUIP-A-pharma program will build a versatile pharmaceutical manufacturing site involving finished pharmaceutical dosage forms and pharmaceutical ingredients initiated at the same location. This will shorten the pharmaceutical raw material supply chain and also reduce supply chain risk for marketing product distribution. The synthesis platform is formed by Battelle, is introduced to potentially synthesize various active pharmaceutical agents while matching all regulatory necessities for the production of these drugs.

The aprecia’s Z-form flex technology platform is built for nimble manufacturing applications as it initiates finished medicines in the primary packaging, providing merged aspects of packaging and manufacturing operations. This technology platform is designed to continuously travel drug product formulation modifications to meet the requirements of medications for a vast patient population.

The program will create major scientific data required for elaborating the potential of agile manufacturing and its suitability for FDA drug product registration, and to produce safe and valuable pharmaceutical products. Additionally, it will enable the vast acceptance of advanced manufacturing technology like Aprecia’s 3D printing technology. The technology uncovers private capital for the marketization of innovative pharmaceutical technology and levels up the nimble pharmaceutical manufacturing technology into the vast marketplace.

The impact of this program is expanding. With this unique program and navigational support from the IBMSC, Aprecia, and Battelle will utilize the nimble pharmaceutical manufacturing technology to identify complex drug shortages more frequently and provide point-of-need manufacturing to contribute to medical countermeasure applications and military operations. This will unlock opportunities for successful personalized medicine to develop and reach certain areas.